Teva, OncoGenex commence phase-3 trial for advanced prostate cancer drug
BOTHELL, Wash. Teva Pharmaceutical Industries and OncoGenex Pharmaceuticals have started a late-stage clinical trial of an investigative treatment for advanced prostate cancer, the two companies said Thursday.
Teva and OncoGenex, a company based in the Seattle suburb of Bothell, Wash., that develops cancer therapies, announced the start of “SYNERGY,” a phase-3 trial of OGX-011/TV-1011 (custirsen), a first-line therapy for treating castrate-resistant prostate cancer.
The trial will take place at around 125 centers around the world and will include 800 patients with CRPC that has spread to other parts of the body. Patients will receive either custirsen with Sanofi-Aventis’ chemotherapy drug Taxotere (docetaxel) and prednisone, or Taxotere and prednisone alone.
Waiting period for Bristol-ZymoGenetics deal expires
NEW YORK The Hart-Scott-Rodino waiting period for Bristol-Myers Squibb’s acquisition of Seattle-based biotech company ZymoGenetics has expired, enabling Bristol’s acquisition to go through, the drug maker said Tuesday.
The drug maker announced the deal to acquire ZymoGenetics for $885 million, or $9.75 per share, earlier this month.
The buyout gives Bristol ownership of Recothrom, a drug used to control bleeding during surgical procedures; an investigative treatment for hepatitis C called pegylated-interferon lambda; and an investigative treatment for melanoma called interleukin-21, or IL-21.
Valeant, Biovail become one
MISSISSAUGA, Ontario The merger between Valeant Pharmaceuticals International and Biovail is complete, the two companies said Tuesday.
Shareholders of both companies have approved the merger, worth more than $3 billion, originally announced in June.
The combined company will take Valeant’s name.